Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Treace Medical Concepts (TMCI) Invested Capital (2020 - 2025)

Treace Medical Concepts' Invested Capital history spans 6 years, with the latest figure at $89.1 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 21.1% year-over-year to $89.1 million; the TTM value through Dec 2025 reached $89.1 million, down 21.1%, while the annual FY2025 figure was $89.1 million, 21.1% down from the prior year.
  • Invested Capital reached $89.1 million in Q4 2025 per TMCI's latest filing, down from $91.0 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $157.6 million in Q1 2023 to a low of $28.5 million in Q1 2021.
  • Average Invested Capital over 5 years is $101.4 million, with a median of $100.8 million recorded in 2021.
  • Peak YoY movement for Invested Capital: soared 130167.09% in 2021, then tumbled 36.12% in 2022.
  • A 5-year view of Invested Capital shows it stood at $93.1 million in 2021, then tumbled by 34.97% to $60.5 million in 2022, then skyrocketed by 127.89% to $137.9 million in 2023, then decreased by 18.16% to $112.9 million in 2024, then dropped by 21.1% to $89.1 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Invested Capital are $89.1 million (Q4 2025), $91.0 million (Q3 2025), and $98.7 million (Q2 2025).